SGLT2 inhibitors and GLP-1 receptor agonists lower cardiovascular risk in type 2 diabetes, but a recent review suggests that ...

In elderly patients 65 years of age or older with heart failure with reduced ejection fraction (HFrEF), regular use of sodium ...

Investigators examined the comparative effectiveness of SGLT2 inhibitors and GLP-1 receptor agonists in a real-world setting.

Secondary analysis findings from the EMPACT-MI trial highlight empagliflozin's significant cardiovascular and kidney benefits when initiated soon after an acute myocardial infarction.

SGLT2 inhibitor use may help stabilize eGFR levels for patients with autosomal dominant polycystic kidney disease and type 2 diabetes, according to study data.“Given its unique pathophysiology, ...

Israel: A new study published in JAMA Network Open highlights a key safety insight for patients with type 2 diabetes taking ...

For patients with acute MI at increased risk for HF, empagliflozin showed cardiorenal benefits and was safe to initiate early ...

After the SGLT2 inhibitors were shown to benefit patients with type 2 diabetes, reducing cardiovascular events, including hospitalization for heart failure, the next natural research question ...

Sodium-glucose cotransporter-2 (SGLT2) inhibitors are a newer type of medication used to help people with diabetes manage ...

A study found that the newer generation of much more effective diabetes medications are reaching only a fraction of the patients who are recommended to take them based on new guidelines.

SGLT2 inhibitors have become a major drug used to treat diabetes, heart failure, and chronic kidney disease. However, there have been questions as to whether it is safe to use these drugs in ...

Despite incomplete evidence, longevity enthusiasts are experimenting with SGLT2 inhibitors in their quest to live healthier for longer.